AGP Executive Report
Last update: 17 minutes agoObesity & Muscle Preservation: Regeneron reported new Phase 2 COURAGE results showing trevogrumab can prevent about 70% of muscle loss linked to semaglutide-induced weight loss, with a follow-up Phase 2 planned for older adults with obesity and low muscle mass. GLP-1 Pipeline Deal: Novo Nordisk agreed to license Hengrui’s experimental once-weekly oral obesity pill HRS-1596 in a deal worth up to US$2.6B (US$300M upfront), aiming to expand oral options for obesity and type 2 diabetes outside mainland China, Hong Kong, Macao and Taiwan. Local Health Services: Macao Union Medical Center outlined holiday arrangements for National Day and the day after, with outpatient and many clinics closed but emergency, inpatient and hemodialysis services operating as usual. Food Safety Alert: Macao’s IAM ordered a recall of a black truffle sauce product (“Familie” Black Truffle Sauce Natural Truffle 5%) after heavy metal total arsenic exceeded limits, urging the public to stop eating the affected batch. Public Health Guidance: Hong Kong’s Department of Health urged healthy lifestyles to combat cardiovascular disease on World Heart Day, highlighting high CVD burden and the need for earlier screening in Asian communities. Safety on the Roads: A taxi failed to give way in Macau, injuring a motorcyclist who was taken to Conde de São Januário Hospital Centre; both drivers passed breath tests.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
